# Tirzepatide Mechanism of Action: GIP and GLP-1 Dual Agonism — SURPASS and SURMOUNT Trial Record > Tirzepatide mechanism of action: imbalanced dual GIP/GLP-1 receptor agonism confirmed by cryo-EM, a five-day half-life, and twelve phase-3 trials. The structural and pharmacological record, cited. The structural pharmacology of a 39-amino-acid synthetic peptide — imbalanced receptor affinities, biased GLP-1R signaling, a five-day half-life, and the twelve phase-3 trials that characterized it in humans. ## How Does Tirzepatide Work? Receptor Pathway Overview Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) simultaneously — an engagement that amplifies insulin secretion, suppresses glucagon, slows gastric emptying, and activates hypothalamic satiety centers to reduce caloric intake [1][19]. The dual engagement is structurally imbalanced. At GIPR, tirzepatide binds with affinity equal to native GIP — full receptor engagement at clinical doses. At GLP-1R, it binds approximately five-fold more weakly than native GLP-1 [1]. This imbalance means that at the GLP-1 receptor, tirzepatide behaves differently from GLP-1-only agents: it preferentially drives cAMP generation over beta-arrestin recruitment, a property termed biased agonism [1]. The consequence is reduced receptor internalization — the receptor remains at the cell surface longer, sustaining insulin secretion rather than internalization-mediated desensitization [1]. Cryo-electron microscopy confirmed the structural basis of this pharmacology. Sun et al. (PNAS 2022) demonstrated that tirzepatide activates GIPR and GLP-1R through distinct structural mechanisms: at GIPR, its N-terminal tyrosine mimics native GIP binding; at GLP-1R, the C20 fatty acid modification reduces beta-arrestin recruitment while the peptide backbone engages the extracellular domain [2]. The combined lipid modification and peptide sequence produce a unique dual-receptor pharmacology unattainable with either native incretin peptide alone [2]. ### How Does Tirzepatide Work? Activates both GIP and GLP-1 receptors simultaneously, augmenting glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing caloric intake via hypothalamic satiety signaling. Its dual agonism also improves insulin sensitivity via adipose tissue GIPR pathways independent of weight loss [1][19]. ### Is Tirzepatide a GLP-1 Agonist? Tirzepatide is a GLP-1 receptor agonist and a GIP receptor agonist — its dual mechanism is the key distinguishing feature versus GLP-1-only agents. At GLP-1R it binds with approximately five-fold lower affinity than native GLP-1 and exhibits biased agonism favoring cAMP over beta-arrestin signaling [1]. ## Tirzepatide as a Synthetic Peptide: Structural Basis of Dual Agonism Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide analog with a molecular weight of 4,813.5 Da. Its primary sequence derives from native GIP, modified at two positions with alpha-aminoisobutyric acid (Aib) residues that resist proteolytic cleavage and extend the peptide's metabolic half-life [1]. A C20 fatty diacid moiety is attached via a gamma-glutamic acid/mini-PEG linker at a lysine residue, enabling high-affinity albumin binding (>99% bound in plasma), which further shields the molecule from degradation and supports the approximately five-day half-life that makes once-weekly dosing feasible [3]. The fatty diacid modification does two things simultaneously: it extends half-life via albumin binding, and it structurally dampens beta-arrestin recruitment at GLP-1R — the same modification that produces the biased agonism responsible for sustained insulin secretion [2]. This dual function of the lipid moiety — half-life extension and signaling bias — appears to be a key engineering insight of the tirzepatide structure [1][2]. ## Tirzepatide Half-Life and Pharmacokinetics Population pharmacokinetic analysis of data from phase 2 and 3 trial participants characterized tirzepatide's PK profile precisely [3]. Half-life is approximately five days in humans — the property that makes once-weekly subcutaneous dosing feasible. A two-compartment PK model describes absorption and distribution; bioavailability after subcutaneous injection is approximately 80%, mean volume of distribution approximately 10.3 L. Peak serum concentrations are reached 8 to 72 hours post-dose. Steady-state plasma concentrations are achieved after approximately four weeks of weekly administration, which corresponds to the four-week titration interval used in SURPASS and SURMOUNT [3]. No dose adjustment for demographic covariates including age, sex, race, or body size subpopulations was required in the population PK model [3]. Greater than 99% of tirzepatide in plasma is albumin-bound. The molecule is cleared as amino acid metabolites through urine and feces following proteolytic degradation [3]. ### How Long Does Tirzepatide Stay in Your System? Tirzepatide has a mean half-life of approximately five days in humans, supporting once-weekly dosing. Steady-state plasma concentrations are reached after approximately four weeks of weekly administration, matching the four-week titration increments used in SURPASS and SURMOUNT [3]. ### What Does Tirzepatide Do to Your Body? In clinical studies, tirzepatide reduced fasting and postprandial glucose, promoted insulin secretion, suppressed glucagon, slowed gastric emptying, reduced caloric intake through central satiety pathways, and reduced body weight and visceral adiposity. It also improved beta-cell function (HOMA2-B increased 96.9–120.4% vs semaglutide's 84.0% in SURPASS-2) and insulin sensitivity (HOMA2-IR reduced 15.5–24.0%) [10][12]. ## Once-Weekly Tirzepatide: Glycemic Efficacy Across SURPASS Trials The SURPASS program enrolled six phase-3 randomized controlled trials in adults with type 2 diabetes, comparing tirzepatide at 5, 10, and 15 mg once weekly against placebo, semaglutide 1 mg, insulin degludec, insulin glargine, and dulaglutide [4][5][6]. **SURPASS-1** (40-week monotherapy, placebo-controlled): tirzepatide reduced HbA1c by 1.87, 1.89, and 2.07 percentage points at 5, 10, and 15 mg versus +0.04% with placebo. Body weight fell 7.0, 7.8, and 9.5 kg. The proportion achieving HbA1c ≤6.5% was 81–86% across doses versus 10% with placebo [4]. **SURPASS-2** (40-week active comparator vs semaglutide 1 mg, 1,879 participants): tirzepatide reduced HbA1c by 2.01, 2.24, and 2.30 percentage points at the three doses versus 1.86 with semaglutide. Weight loss was 7.6, 9.3, and 11.2 kg versus 5.7 kg with semaglutide. All three tirzepatide doses were superior to semaglutide 1 mg for HbA1c reduction; the 10 and 15 mg doses were superior for weight reduction [5]. **SURPASS-1 to -5 pooled analysis** (N = 6,263 tirzepatide participants): proportions achieving the composite endpoint of HbA1c <7.0% with at least 5% weight loss and no hypoglycemia ranged from 43% to 82% with tirzepatide versus 4–5% with placebo — a composite unattainable with prior agents in substantial proportions of trial participants [6]. SURPASS-3 and SURPASS-4 demonstrated superiority over basal insulin comparators (insulin degludec and insulin glargine, respectively) for both glycemic and weight endpoints [6]. ### How Effective Is Once-Weekly Tirzepatide for Diabetes Outcomes? SURPASS-1 through -5 demonstrated HbA1c reductions of 1.87 to 2.59 percentage points across the 5–15 mg dose range. Across the pooled cohort of 6,263 participants, 43–82% achieved the composite glycemic-and-weight target of HbA1c <7% with ≥5% weight loss and no hypoglycemia [6]. ### What Are the Long-Term Effects of Tirzepatide? SURMOUNT-1 72-week data showed sustained weight loss without plateau at 15 mg. SURMOUNT-4 established the chronic-treatment context: after discontinuation following 36 weeks of tirzepatide (mean −20.9% weight), participants regained a mean of 14.0% body weight over 52 weeks, while those continuing tirzepatide lost a further 5.5%. Only 16.6% of participants who stopped maintained at least 80% of their initial loss, versus 89.5% in the continuation group [9]. ## Tirzepatide vs Semaglutide: Comparative Clinical Trial Data SURPASS-2 is the only completed phase-3 head-to-head trial. It randomized 1,879 participants with type 2 diabetes to tirzepatide at 5, 10, or 15 mg versus semaglutide 1 mg once weekly for 40 weeks [5]. At all three tirzepatide doses, HbA1c reduction was superior to semaglutide 1 mg (differences: −0.15, −0.39, and −0.45 percentage points). For weight, tirzepatide 10 and 15 mg were superior to semaglutide 1 mg (differences: −3.6 and −5.5 kg). Gastrointestinal adverse event profiles were similar between agents [5]. An analysis of SURPASS-2 data focused on markers of islet cell function and insulin sensitivity found that tirzepatide produced superior improvements in HOMA2-B (beta-cell function: +96.9–120.4% vs semaglutide's +84.0%) and HOMA2-IR (insulin resistance: −15.5–24.0% vs semaglutide's −5.1%) [10]. The GIP receptor agonism unique to tirzepatide is attributed to this insulin sensitization component beyond weight loss effects [10]. Critical methodological context: SURPASS-2 compared tirzepatide against semaglutide at the 1 mg dose, which is a diabetes-indication dose and lower than the 2.4 mg dose studied for obesity. A direct head-to-head comparison against semaglutide 2.4 mg for weight outcomes was not in the completed phase-3 dossier as of 2025; SURPASS-CVOT used dulaglutide as its active comparator [14]. ### Is Tirzepatide Better Than Semaglutide? SURPASS-2 compared tirzepatide (5/10/15 mg) to semaglutide 1 mg; tirzepatide produced greater HbA1c reduction at all doses and greater weight loss at 10 and 15 mg. Tirzepatide also produced superior HOMA2-B and HOMA2-IR improvements, attributable to its additional GIPR agonism [5][10]. Direct comparison at semaglutide 2.4 mg for weight remains an active research area. ### What Is the Difference Between Tirzepatide and Semaglutide? Semaglutide is a GLP-1 receptor agonist only. Tirzepatide adds full GIP receptor agonism and exhibits biased GLP-1R signaling, which independently promotes insulin sensitization via adipose tissue pathways and may additively enhance adipose tissue metabolism and energy expenditure beyond GLP-1 effects alone [1][10][19]. ### Tirzepatide and Sleep Apnea: SURMOUNT-OSA Trial Data SURMOUNT-OSA (2024) enrolled adults with moderate-to-severe obstructive sleep apnea and obesity in two parallel phase-3 RCTs (PAP-user and non-PAP-user populations). Tirzepatide reduced the apnea-hypopnea index by approximately 25 events/hour (non-PAP trial) and approximately 29 events/hour (PAP-user trial) versus 5–6 events/hour for placebo over 52 weeks [13]. The effect was primarily mediated by weight reduction and visceral adiposity loss rather than a direct airway mechanism. Hypoxic burden, hsCRP, and systolic blood pressure also improved [13]. --- An engraved reading room for the published SURPASS and SURMOUNT record — trial findings rendered in brass, not a clinic and not a prescription.